AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): a guide to its use

    loading  Checking for direct PDF access through Ovid

Abstract

The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine is indicated for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. The vaccine elicits a high immunogenic response and is highly protective against cervical intraepithelial neoplasia and infection. It is also generally well tolerated, and cost effective from a healthcare payer perspective.

Related Topics

    loading  Loading Related Articles